Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
24 oct. 2024 09h15 HE
|
Cyclacel
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
28 août 2024 14h48 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
06 août 2024 09h26 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
24 mai 2024 16h30 HE
|
BIO-key International, Inc.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq regarding untimely filing of its form 10-Q.
Evaxion Receives Nasdaq Notification
10 mai 2024 17h00 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Auddia Announces Closing of $2.3M PIPE to Eliminate Debt and Regain Nasdaq Compliance
29 avr. 2024 08h00 HE
|
Auddia Inc.
BOULDER, CO, April 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), a developer of a proprietary AI platform for audio and...
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
22 avr. 2024 16h30 HE
|
BIO-key International, Inc.
BIO-key International, Inc. Received Notice of Non-Compliance from Nasdaq regarding filing all required periodic financial reports with the SEC.
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 févr. 2024 08h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
08 janv. 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
03 nov. 2023 16h30 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...